• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Express Scripts

Cigna lowers insulin price to $25 per month

April 3, 2019 By Nancy Crotti

Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients. Three firms — Eli Lilly, Novo Nordisk and Sanofi — control 90% of the global insulin market and produce all the insulin used in the U.S. […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), News Well, Pharmaceutical, Regulatory/Compliance Tagged With: Cigna, Eli Lilly & Co., Express Scripts, FDA, Novo Nordisk, Sanofi

Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug

May 1, 2018 By Sarah Faulkner

Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive spot on the pharmacy benefit manager’s national formulary. The agreement, effective July 1, is designed to broaden patient access to the injectable medicine and lower out-of-pocket costs for eligible […]

Filed Under: Cardiovascular, Pharmaceutical, Wall Street Beat Tagged With: Express Scripts, Regeneron, Sanofi-Aventis

Propeller Health, Express Scripts ink smart inhaler sensor deal

November 16, 2017 By Fink Densford

Propeller Health said today it inked a strategic partnership deal with Express Scripts (NSDQ:ESRX) to provide Propeller’s digital solutions to Express Script members. Through the deal, St. Louis-based Express Script members will be able to use inhaler sensors and connected mobile applications to manage their asthma or chronic obstructive pulmonary disease. The companies touted it as the largest […]

Filed Under: Business/Financial News, Drug-Device Combinations, Patient Monitoring, Respiratory Tagged With: Express Scripts, Propeller Health

OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017

November 9, 2017 By Sarah Faulkner

OncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Anika Therapeutics Inc., bostonbiomedical, BrainStorm Cell Therapeutics Inc., DelMar Pharmaceuticals, Express Scripts, GlaxoSmithKline plc, OncoSec Medical, Pulmatrix Inc.

Express Scripts, other PBMs named in lawsuit over pricey EpiPens

August 31, 2017 By Sarah Faulkner

Express Scripts (NSDQ:ESRX) and other pharmacy benefit managers have been accused of giving Mylan‘s (NSDQ:MYL) EpiPens favorable placement on drug formularies in exchange for kickbacks, according to a proposed class action filed in Kansas federal court this week. The suit was brought by people covered under Employee Retirement Income Security Act benefit plans. These consumers claim that […]

Filed Under: Business/Financial News, Drug-Device Combinations, Legal News, Pharmaceutical, Wall Street Beat Tagged With: Express Scripts, Mylan

Express Scripts covers Mylan’s EpiPen on 2018 formulary, excluding rivals

August 1, 2017 By Sarah Faulkner

Express Scripts (NSDQ:ESRX) said yesterday that it would include Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax Laboratories (NSDQ:IPXL)  and Kaleo. The largest pharmacy benefit manager in the U.S. has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards the high prices taken […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Express Scripts, Impax Laboratories, Kaleo Inc, Mylan

Express Scripts, CVS sued over Mylan’s EpiPen

June 6, 2017 By Sarah Faulkner

Express Scripts (NSDQ:ESRX) and CVS Health (NYSE:CVS) were among the pharmacy benefit managers named in a lawsuit last week, when a potential class of patients accused them of violating the Employee Retirement Income Security Act by failing to negotiate lower prices for Mylan’s EpiPen allergy auto-injector. The suit, filed in the Minnesota District Court, alleges that […]

Filed Under: Drug-Device Combinations, Legal News, Pharmaceutical, Wall Street Beat Tagged With: CVS Health, Express Scripts, Mylan

EpiPen purchasers level class action against Mylan over price hikes

April 4, 2017 By Sarah Faulkner

Mylan (NSDQ:MYL) was hit with another class action lawsuit over the price of its EpiPen device yesterday. The lawsuit, which was filed in the Washington Western District Court, alleges that Mylan engaged in a scheme with pharmacy benefit managers to dominate the market and overcharge customers. Although the Canonsburg, Penn.-based company has been hit with several lawsuits […]

Filed Under: Drug-Device Combinations, Legal News, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: CVS Health, Express Scripts, Mylan

Eli Lilly, Express Scripts offer insulin discount program

December 14, 2016 By Sarah Faulkner

Eli Lilly (NYSE:LLY) said it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans. The program will begin January 1, 2017 and will cover Lilly’s insulins Humalog, Humulin, and the biologic Basaglar. Lilly said it anticipates the program […]

Filed Under: Diabetes, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: CVS Health, Eli Lilly & Co., Express Scripts, Novo Nordisk

Health services provider says Ernst & Young stole trade secrets | MassDevice.com On Call

February 22, 2013 By Arezu Sarvestani Leave a Comment

MassDevice On Call

MASSDEVICE ON CALL — Pharmaceutical management services giant Express Scripts Holding Co. sued accounting firm Ernst & Young, claiming that an E&Y employee sneaked into Express Scripts offices to steal trade secrets.

Express Scripts fingered Don Gravlin, a partner at E&Y, for the alleged misconduct, saying Gravlin and the company "were possessed with an evil motive" in stealing more than 20,000 pages of pricing information, projections and other confidential data, according to the legal complaint.

Filed Under: Legal News, News Well Tagged With: American College of Cardiology, Ernst & Young, Express Scripts, On Call

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS